Generated by AI
Summary of Jul 20's posts. Generated by AI.
Summary of Dec 24's posts. Generated by AI.
Summary of Jul 20's posts. Generated by AI.
Investors talking about XCUR also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.
Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for blood-related diseases and other serious medical conditions. Its current focus includes small-molecule medicines designed to influence cellular signaling and mobilization, particularly through inhibition of the CXCR4 chemokine receptor. The company’s lead clinical-stage asset, GPC-100, also known as burixafor, is being evaluated for its ability to mobilize hematopoietic stem cells and lymphocytes, supporting potential applications in hematology and oncology. Exicure, Inc. also maintains expertise in nucleic-acid-based drug development, including therapeutic platforms centered on spherical nucleic acids for immuno-oncology and genetic disorders. As a clinical-stage biotechnology business, the company’s role in the financial market is linked to the development and advancement of specialized pharmaceutical candidates rather than the commercial sale of a broad portfolio of approved medicines. Its activities place it within the biotechnology and pharmaceutical sectors, serving research, clinical-development, and healthcare markets.
Website400 Seaport Court
Redwood City, CA, 94063
United States
The latest articles about XCUR.
WILMINGTON, Del., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (“Exicure” or the “Company”) today announced that on November 4, 2026, the Company and its wholly owned subsidiary, GPCR Therapeutics USA Inc. (“GPCR USA”), entered into an Intellectual Property, Asset and License Assignment Agreement (the “Agreement”) with GPCRT Inc. (“GPCRT”), a company organized under the laws of the Republic of Korea, under which GPCRT has agreed to acquire the Company’s GPC-100 (burixafor) prog